Unlike blocking antibodies, it is a tremendous challenge to select antibody candidates with agonistic function to boost various components in the immune system.  We have successfully developed a set of in vitro agonistic function assays, which facilitate the process of large-scale screening. CALS™ Platform, one of our proprietary technologies, has been proved to be a robust tool in our agonist discovery and development.